eligibility_summary
Adults (≥18) with ECOG 0–2, ≥3‑mo survival, path‑confirmed solid tumor refractory to standard therapy, B7‑H3 IHC ≥1+ with ≥50% membrane staining, measurable disease (RECIST 1.1), adequate counts and renal/hepatic/cardiac/pulmonary function, consent. Exclude recent immunosuppressants, recent stroke/seizure, active HBV/HCV/HIV/EBV/CMV/syphilis, serious cardiac/unstable/neuro disease, unresolved >G2 toxicity, GVHD, active infection, pregnancy plans ≤2 yrs, other trials <1 mo, CNS disease, bulky liver mets, or unsuitable.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: UTAA06, a B7-H3–targeted chimeric antigen receptor γδ T cell (CAR-γδ T) therapy (biological/cellular immunotherapy). Single infusion with dose-escalation (1×10^8–1×10^9 CAR+γδT). Mechanism of action: γδ T cells are engineered with a CAR specific for B7-H3 (CD276) to redirect MHC-independent cytotoxicity toward B7-H3–expressing tumor cells. CAR signaling boosts activation, expansion, and tumor killing via perforin/granzyme release and cytokines. Targets/cells/pathways: Tumor cell surface B7-H3 (pan-tumor antigen) on advanced solid tumors, engagement of engineered γδ T-cell effector pathways and immune synapse formation against B7-H3+ lesions. Phase: Early phase/Phase 1, single-arm.